Effect of basal insulin therapy on vascular endothelial function and adipokine profiles in people with Type 2 diabetes

Abstract

These results suggest that the effect on endothelial function and adipocytokine profiles may differ between glargine and detemir in people with diabetes (Trial registration ID: UMIN000004973).

A randomised controlled trial evaluating the impact of targeted vitamin D supplementation on endothelial function in type 2 diabetes mellitus: The DIMENSION trial

“…The use of basal insulin and angiotensin receptor blockers (ARBs) were higher in the placebo group ( p = 0.05). The use of basal insulin has been associated positively with EF, 16 hence we adjusted for this in the multivariate analysis. The baseline RHI was slightly higher in the placebo group when compared to the vitamin D group; although this difference was not statistically significant, we adjusted for baseline RHI as well in the final analysis.…”

Comparative effectiveness and harms of long‐acting insulins for type 1 and type 2 diabetes: A systematic review and meta‐analysis

“…For patients with type 2 diabetes, evidence comparing detemir and glargine came from 10 trials. [42][43][44][45][46][47][48][49][50][51] We rated three of the newer trials poor quality because of concerns with randomization, blinding and attrition. [49][50][51] The total number of patients in the remaining fairquality trials was 2762, with 12-52 weeks of treatment.…”

“…[42][43][44][45][46][47][48][49][50][51] We rated three of the newer trials poor quality because of concerns with randomization, blinding and attrition. [49][50][51] The total number of patients in the remaining fairquality trials was 2762, with 12-52 weeks of treatment. We included 12 observational studies (eight with hypoglycaemia outcomes 40,[52][53][54][55][56][57][58] and four with cancer outcomes [59][60][61][62] ), of which one was poor quality.…”

Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance

“…(2016) на основании анализа национальных регистров Финляндии, включив-шего 23 751 пациента с СД2 в возрасте >40 лет, начавших применение базального инсулина в период 2006-2009 гг., показали, что применение детемира ассоциируется с луч-шей выживаемостью (рис. 1), снижает общую смертность на 61% в сравнении с НПХ и на 29% в сравнении с глар-гином, а также смертность от сердечно-сосудистых за-болеваний и злокачественных новообразований на 58% в сравнении с инсулином НПХ [61]. Данные Makino H. и соавт.…”